Toll-free:1-888-852-8623

All categories

  • All categories
  • Flow Cytometry Antibodies
  • ELISA Kits
  • MACS Cell Isolation
  • Antibodies and Reagents
  • Apoptosis and Cell Health Detection
  • Metabolism Assays
  • Immunoassays
  • Cell Identification Kits
  • Proteins and Peptides
  • Cell Culture
Please enter the item number/product keyword!
Keyword cannot be empty !
INSERT SYMBOLS:
  • α
  • β
  • γ
  • δ
  • ε
  • ζ
  • η
  • θ
  • κ
  • μ
  • ω
  • σ
  • τ
  • λ
  • ⅩⅢ
  • ⅩⅢ
  • ⅩⅣ
  • ⅩⅤ
  • ⅩⅦ
  • ⅩⅧ
  • UP ↑

Recombinant Human CLDN18.2/Claudin-18 A2 Protein (His Tag) (PKSH033470)

All Size Price Qty
50μg $ 438.00
10μg $ 198.00
Add to cart

For research use only.

Synonyms CLDN18, Claudin-18
Species Human
Expression Host E.coli
Sequence Asp28-Leu76
Accession P56856-2
Calculated Molecular Weight 19.7 kDa
Observed Molecular Weight 18 kDa
Tag N-His
Bio-activity Not validated for activity
Purity > 95 % as determined by reducing SDS-PAGE.
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method.
Storage Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.
Shipping This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at < - 20°C.
Formulation Supplied as a 0.2 μm filtered solution of 25mM Tris-HCl, 25mM NaCl, 0.1% Triton X-100, 10% glycerol, 0.1mM GSH, 0.01mM GSSG, pH 8.0.
Reconstitution Not Applicable
Background Claudin-18(CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.
Other Clones

{{antibodyDetailsPage.numTotal}} Results

Other Formats

{{formatDetailsPage.numTotal}} Results

  • IF:{{item.impact}}

    Journal:{{item.journal}} ({{item.year}})

    DOI:{{item.doi}}

    Reactivity:{{item.species}}

    Sample Type:{{item.organization}}

  • Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}